2016
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisPD-1 inhibitor therapyInhibitor therapyInterstitial nephritisLung cancerNon-small cell lung cancerAnti-PD-1 antibodyAcute kidney injuryImmune checkpoint inhibitorsT cell immunityCell lung cancerLung cancer patientsClinical trial dataRenal toleranceCheckpoint inhibitorsKidney injuryDeath-1Kidney biopsyCancer patientsPatientsTrial dataTherapyAdverse effectsDrugsNephritis
2010
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Flanigan J, Deshpande H, Gettinger S. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics: Targets And Therapy 2010, Volume 4: 237-243. PMID: 20859451, PMCID: PMC2943196, DOI: 10.2147/btt.s7223.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerClinical trialsAdvanced non-small cell lung cancerPhase II clinical trial dataRandomized phase III trialOral small-molecule inhibitorNSCLC clinical trialsPhase III trialsGrowth factor receptor 2Vascular endothelial growth factor receptor 2Endothelial growth factor receptor 2Clinical trial dataFactor receptor 2Growth factor receptorOral agentsIII trialsDaily doseMultiple malignanciesReceptor 2Small molecule inhibitorsUS FoodDrug Administration